ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

First, select a broad health condition.
3 results sorted by trial registration date.
Clear all

  • Intensive treatment of Pediatric Obsessive Compulsive Disorder (OCD): Improving access and outcomes

    The aim of the study is to examine whether D-Cycloserine can augment graded exposure therapy for children and adolescents with Obsessive Compulsive Disorder. D-Cycloserine is an antibiotic drug traditionally used to treat tuberculosis. D-Cycloserine is a glutamatergic partial N-methyl-D-aspartate (NMDA) agonist, which has recently been shown to facilitate fear extinction in humans and animals and has also demonstrated to improve treatment outcome when combined with exposure therapy in social phobia, acrophobia, or fear of heights and OCD in adult samples. The drug has recently been used to augment exposure therapy for children and adolescents with OCD. A secondary aim of the study is to systematically examine the timing of D-Cycloserine augmentation in a pediatric sample by comparing D-Cycloserine given immediately before or immediately after exposure therapy.

    Registration number:
    ACTRN12614000140651
    Broad health category:
    • Mental Health
    Specific health category:
    • Other mental health disorders
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • QLD
    Gender:
    • All

  • Novel Treatment of Phobias in Children and Teenagers

    The aim of this trial is to examine whether D-Cycloserine can augment a single session of graded exposure therapy in children and adolescents with a specific phobia. D-Cycloserine is an antibiotic drug traditionally used to treat tuberculosis. D-Cycloserine is a glutamatergic partial N-methyl-D-aspartate (NDMA) agonist, which has recently been shown to facilitate fear extinction in humans and animals and has also demonstrated to improve treatment outcome when combined with exposure therapy in social phobia, acrophobia or fear of heights and OCD in adult samples. The drug has recently been successfully used to augment exposure therapy for children and adolescents with OCD.

    Registration number:
    ACTRN12612000420842
    Broad health category:
    • Mental Health
    Specific health category:
    • Anxiety
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • A Novel Approach to Treatment Refractory Childhood Obsessive-Compulsive Disorder: D-Cycloserine Augmented Behaviour Therapy

    This research aims to provide preliminary data on a randomised controlled treatment trial for treatment refractory childhood obsessive-compulsive disorder (OCD) – that is, children and adolescents with OCD who continue to suffer disability even after first-line evidence-based treatment. Treatment evaluated in this study will be 5 (+3) sessions augmented behaviour therapy, specifically intensive exposure and response prevention, with D-Cycloserine – an antibiotic drug traditionally used to treat tuberculosis. D-Cycloserine is a glutamatergic partial N-methyl-D-aspartate (NMDA) agonist, which has recently been shown to facilitate fear extinction in humans and animals and has also demonstrated to improve treatment outcome when combined with exposure therapy in social phobia, acrophobia or fear of heights, and OCD in adult samples. This drug is yet to be investigated in a sample of children and youth with OCD.

    Registration number:
    ACTRN12609000370202
    Broad health category:
    • Mental Health
    Specific health category:
    • Other mental health disorders
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • Not specified
    Gender:
    • All
Tags:
  • Finding clinical trials